The Pharma Data

DECEMBER 17, 2020

Regardless of their decisions or which treatment they receive, all participants will be monitored for two years. Currently, healthcare personnel and long-term care facility residents participating in their trial are the only ones who can opt to receive the vaccine.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

JANUARY 26, 2021

While the preliminary nature of Phase 2 results from COVID-19 neutralizing monoclonal antibodies may have limited acceptance of treatment, these Phase 3 data further strengthen the available evidence,” said Daniel Skovronsky, M.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52